Log in to search using one of your social media accounts:

 

An MS Drug Update An MS Drug Update
Cutting the risk for natalizumab-related PML, update on disability outcomes with ibudilast, and daclizumab pulled from the global market.Medscape Neurology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 29, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery Commentary Source Type: news

JC Virus May Be Undetectable in CSF in Some Patients With Small PML Lesions JC Virus May Be Undetectable in CSF in Some Patients With Small PML Lesions
JC virus (JCV) may be undetectable in the cerebrospinal fluid (CSF) of natalizumab-treated patients with multiple sclerosis (MS) who have small progressive multifocal leukoencephalopathy (PML) lesions, according to a retrospective study.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - March 14, 2018 Category: Pathology Tags: Neurology & Neurosurgery News Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: Nuevo factor de riesgo para la leucoencefalopat ía multifocal progresiva (PML por sus siglas en inglés) relacionado con Tysabri (natalizumab)
El 20 de enero del 2012, la Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) informó al público que ha identificado como factor de riesgo para la leucoencefalopatía multifocal progresiva (PML por sus siglas en inglés) la detección en pruebas de anticuerpos contra el virus JC. PML es una in fección poco común pero grave del cerebro relacionada con el uso de Tysabri (natalizumab) para el tratamiento de esclerosis múltiple o enfermedad de Crohn. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 13, 2018 Category: Drugs & Pharmacology Source Type: news

Topline Results Negative for MS Drug in Acute Stroke Topline Results Negative for MS Drug in Acute Stroke
After natalizumab showed some initial promise in improving clinical outcomes in acute ischemic stroke in a phase 2a study, a phase 2b trial of the drug finds no clinical benefit.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 9, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Pregnant MS Patients Face Extra Relapse Risk with Natalizumab Holiday (CME/CE)
(MedPage Today) -- Avoiding washout, resuming treatment early may improve outcomes (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - February 8, 2018 Category: Neurology Source Type: news

MS Drug Poses Hard Choices for Women Wanting Kids
Those who take Tysabri (natalizumab) to manage their MS are more likely to suffer a relapse during pregnancy if they stop taking the drug before they conceive, the first study found. (Source: WebMD Health)
Source: WebMD Health - February 8, 2018 Category: Consumer Health News Source Type: news

MS Drug Tysabri (Natalizumab) Poses Hard Choices for Women Wanting Children
THURSDAY, Feb. 8, 2018 -- A powerful multiple sclerosis drug presents women with a tough dilemma if they would like to have children, a pair of new studies suggests. Those who take Tysabri (natalizumab) to manage their MS are more likely to suffer... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 8, 2018 Category: General Medicine Source Type: news

Biogen stops testing Tysabri to treat stroke after study fails
(Reuters) - Biogen Inc said on Wednesday it would stop developing its multiple sclerosis drug Tysabri to treat patients with acute ischemic stroke after it failed a mid-stage study. (Source: Reuters: Health)
Source: Reuters: Health - February 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Biogen stops developing Tysabri to treat stroke after failed study
(Reuters) - Biogen Inc said on Wednesday it would stop developing Tysabri to treat acute ischemic stroke patients after the drug failed to meet the main goal of a mid-stage study. (Source: Reuters: Health)
Source: Reuters: Health - February 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Less Frequent Natalizumab Dosing Dramatically Reduces PML Risk Less Frequent Natalizumab Dosing Dramatically Reduces PML Risk
Extended-interval dosing of natalizumab was associated with a 94% lower risk for progressive multifocal leukoencephalopathy vs standard dosing in patients with MS positive for anti-JC virus antibody.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 3, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Extending dosing intervals reduces deadly side effect risk from multiple sclerosis drug
(NYU Langone Health / NYU School of Medicine) A commonly-prescribed multiple sclerosis (MS) infusion medication, natalizumab, linked to a rare but serious side effect is safer to use when dosing intervals are extended, according to a new study led by MS specialists at NYU Langone Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 2, 2018 Category: International Medicine & Public Health Source Type: news

Rituximab Outperforms Other Drugs in RRMS Rituximab Outperforms Other Drugs in RRMS
In a new study, rituximab was superior to other drugs -- including fingolimod, natalizumab, and dimethyl fumarate -- in efficacy, safety, and tolerability in patients with relapsing-remitting MS.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 11, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Dimethyl Fumarate: A Possible Exit Strategy From Natalizumab Dimethyl Fumarate: A Possible Exit Strategy From Natalizumab
Is dimethyl fumarate effective in preventing disease rebound after natalizumab discontinuation in patients with MS?Journal of Neurology, Neurosurgery, and Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 22, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab)
[01-20-2012] The U.S. Food and Drug Administration (FDA) is informing the public that testing positive for anti-JC virus (JCV) antibodies has been identified as a risk factor for progressive multifocal leukoencephalopathy (PML). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 11, 2017 Category: Drugs & Pharmacology Source Type: news

Natalizumab Beneficial in Secondary Progressive MS? Natalizumab Beneficial in Secondary Progressive MS?
A new post hoc analysis of the ASCEND trial in secondary progressive multiple sclerosis suggests that natalizumab is effective in this population, particularly for upper limb function.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 21, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

PML Reported in Patient Receiving Ocrelizumab PML Reported in Patient Receiving Ocrelizumab
But the case could be attributable to'carryover'from the patient's previous treatment with natalizumab, the company said.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Genentech Reports PML Case with Ocrelizumab
(MedPage Today) -- Occurred in patient transitioning from natalizumab (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 24, 2017 Category: Primary Care Source Type: news

Enhanced Atypical Lymphocytes in Natalizumab - Treated MS
Enhanced fraction of atypical lymphocytes, especially binucleated and plasmacytoid lymphocytes (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 24, 2017 Category: Cancer & Oncology Tags: Internal Medicine, Neurology, Oncology, Pathology, Pharmacy, Journal, Source Type: news

March's top stories: Perrigo's $2.85bn sale, Cancer Research UK's Precision Panc project
Perrigo completed the sale of Tysabri drug royalty to RPI for $2.85bn, London's Institute of Cancer Research (ICR) revealed new secrets about the genetic causes of cancer, and Eli Lilly acquired CoLucid Pharmaceuticals for $960m. Pharmaceutical-techn … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 2, 2017 Category: Pharmaceuticals Source Type: news

Perrigo completes sale of Tysabri drug royalty to RPI for $2.85bn
Drug manufacturer Perrigo has completed the sale of its right to the royalty stream from the global net sales of the drug Tysabri (natalizumab) to Royalty Pharma's (RPI) affiliate RPI Finance Trust for $2.85bn. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 27, 2017 Category: Pharmaceuticals Source Type: news

Perrigo to sell Tysabri drug royalty to RPI for $2.85bn
Ireland-based Perrigo has signed an agreement to sell its right to the royalty stream from the global net sales of the multiple sclerosis drug Tysabri (natalizumab) to Royalty Pharma ’s (RPI) affiliate RPI Finance Trust for $2.85bn. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 1, 2017 Category: Pharmaceuticals Source Type: news

Federal investigators subpoena Biogen over MS drug prices
Biogen (NSDQ:BIIB) said on Thursday that it received a subpoena in December last year from federal investigators about the prices of its top-selling multiple sclerosis drugs, Tecfidera, Avonex, Tysabri and Plegridy. In its annual regulatory filing, the company wrote that the investigators inquired about “government price reporting, rebate payments and Biogen’s co-pay assistance programs.” While Cambridge, Mass.-based Biogen said it was cooperating with the federal probe, it did not provide any other specific details. Get the full story at our sister site, Drug Delivery Business News. T...
Source: Mass Device - February 3, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Legal News Neurological Pharmaceuticals Wall Street Beat Biogen Source Type: news

Biogen subpoenaed by federal government over MS drug prices
Biogen disclosed Thursday that it received a subpoena late last year from federal investigators related to the price of its top multiple sclerosis drugs, including blockbuster treatment Tecfidera. Cambridge-based Biogen (Nasdaq: BIIB) said in its annual federal filing that it had received a subpoena on Dec. 5 seeking information regarding "government price reporting, rebate payments and Biogen's co-pay assistance programs" for MS drugs Tecfidera, Avonex, Tysabri and Plegridy. The company sa id it… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 2, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Biogen subpoenaed by federal government over MS drug prices
Biogen disclosed Thursday that it received a subpoena late last year from federal investigators related to the price of its top multiple sclerosis drugs, including blockbuster treatment Tecfidera. Cambridge-based Biogen (Nasdaq: BIIB) said in its annual federal filing that it had received a subpoena on Dec. 5 seeking information regarding "government price reporting, rebate payments and Biogen's co-pay assistance programs" for MS drugs Tecfidera, Avonex, Tysabri and Plegridy. The company sa id it… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 2, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Elevated Natalizumab Levels in MS May Not Be Linked With PML Risk Elevated Natalizumab Levels in MS May Not Be Linked With PML Risk
In multiple sclerosis (MS) patients treated with natalizumab, the risk of developing progressive multifocal leukoencephalopathy (PML) does not appear to be associated with high blood levels of the drug, preliminary research from the Netherlands suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 3, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Perrigo to review options for Multiple Sclerosis drug Tysabri
(Reuters) - Perrigo Co Plc reported a higher-than-expected adjusted quarterly profit and said it would review strategic options for royalty rights from sales of multiple sclerosis drug Tysabri. (Source: Reuters: Health)
Source: Reuters: Health - November 10, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Alemtuzumab Comparison Data Show Some Surprises Alemtuzumab Comparison Data Show Some Surprises
New observational propensity-matched data on head-to-head comparisons of alemtuzumab with beta-interferon, fingolimod, and natalizumab show some unexpected findings.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 29, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

MRI May Help Differentiate Asymptomatic PML From New MS Lesions MRI May Help Differentiate Asymptomatic PML From New MS Lesions
MRI criteria can be used to differentiate asymptomatic progressive multifocal leukoencephalopathy (PML) from new multiple sclerosis (MS) lesions during natalizumab pharmacovigilance, researchers from the Netherlands report.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 21, 2016 Category: Radiology Tags: Neurology & Neurosurgery News Source Type: news

Registry Data: Lemtrada More Effective than Competing MS Tx
(MedPage Today) -- Better than fingolimod or interferon; comparable to natalizumab (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - September 17, 2016 Category: Journals (General) Source Type: news

ECTRIMS: Rituximab Beats MS Drugs in Swedish Registry Study (CME/CE)
(MedPage Today) -- Finds survival advantage for rituximab over fingolimod and natalizumab (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - September 16, 2016 Category: Consumer Health News Source Type: news

Extended Interval Dosing of Natalizumab in Multiple Sclerosis Extended Interval Dosing of Natalizumab in Multiple Sclerosis
Could risk of PML with natalizumab be reduced in MS patients, without compromising efficacy, by extending the interval between doses?Journal of Neurology, Neurosurgery, and Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 12, 2016 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Tysabri (Natalizumab) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 1, 2016 Category: Drugs & Pharmacology Source Type: news

Relapses Rebound in Patients With MS Stopping FingolimodRelapses Rebound in Patients With MS Stopping Fingolimod
As seen with natalizumab, a new study shows patients may experience rebound in relapses after stopping fingolimod. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 12, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Natalizumab Misses Endpoint in Secondary Progressive MSNatalizumab Misses Endpoint in Secondary Progressive MS
In the ASCEND trial, treatment did not delay disease progression, the primary endpoint, although there was a benefit on upper-extremity function. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 26, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Rituximab outperforms fingolimod after natalizumab switch
Rituximab is more effective and better tolerated than fingolimod for patients with multiple sclerosis needing to switch from natalizumab due to JC-virus antibody positivity, research suggests. (Source: MedWire News)
Source: MedWire News - April 26, 2016 Category: Consumer Health News Tags: Multiple sclerosis Source Type: news

Tysabri No Help in SPMS
(MedPage Today) -- Drug didnt reduce disability progression but may benefit upper limb function (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 22, 2016 Category: Primary Care Source Type: news

Rituximab is superior to fingolimod for certain patients with multiple sclerosis
A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab. The study included patients infected with JC virus, which is present in approximately 50% of the general population. While the virus generally causes no problems under normal circumstances, it can cause progressive multifocal leukoencephalopathy (PML), a serious demyelinating disease of the brain, in patients with immune deficiencies due to disease or immunosuppressant drugs. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 21, 2016 Category: Science Source Type: news

Rituximab bests fingolimod in MS patients switching from natalizumab
For patients with relapsing-remitting multiple sclerosis (RRMS) switching to other therapies due to positive JC virus serology, treatment with rituximab resulted in a lower rate of clinical relapse... (Source: Clinical Neurology News)
Source: Clinical Neurology News - April 4, 2016 Category: Neurology Source Type: news

What Genetics are Associated with Multiple Sclerosis?
Discussion Multiple sclerosis (MS) is “a chronic degenerative, often episodic disease of the central nervous system marked by patchy destruction of the myelin that surrounds and insulates nerve fibers, usually appearing in young adulthood and manifested by one or more mild to severe neural and muscular impairments, as spastic weakness in one or more limbs, local sensory losses, bladder dysfunction, or visual disturbances.” It is a chronic disease and therefore symptoms must occur more than once. The first episode is called an acute demyelinating attack. Fifteen to forty-five percent of children with their first...
Source: PediatricEducation.org - April 4, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Could MS Drug Have a Role in Acute Stroke?Could MS Drug Have a Role in Acute Stroke?
A new study looking at natalizumab to treat stroke showed no effect on the primary endpoint of infarct volume growth, but there was a hint of some clinical benefit. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 7, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

No Benefit for Natalizumab Within 9 Hours of Stroke (CME/CE)
(MedPage Today) -- Early data found no benefit on MRI or NIHSS scores for potent monoclonal antibody (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 19, 2016 Category: Cardiology Source Type: news

New EMA Advice for PML Prevention With Tysabri in MSNew EMA Advice for PML Prevention With Tysabri in MS
The European Medicines Agency has released new recommendations on PML prevention with natalizumab in multiple sclerosis. News Alerts (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - February 12, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Natalizumab Ups JCV Seroconversion, Antibody Index in MSNatalizumab Ups JCV Seroconversion, Antibody Index in MS
New data shed some light on the mechanism behind the PML risk with natalizumab and emphasize the need for regular JC virus testing, researchers say. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 30, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Stratification of Natalizumab-Associated PML RiskStratification of Natalizumab-Associated PML Risk
This consensus paper presents a practical algorithm which can be used to stratify patients with MS according to their risk of developing PML during treatment with natalizumab. Journal of Neurology, Neurosurgery, and Psychiatry (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - January 28, 2016 Category: Pathology Tags: Neurology & Neurosurgery Journal Article Source Type: news

MS Drug Tied to Higher Risk for Brain Virus
Patients taking Tysabri were more prone to show signs of exposure to JCV, which can cause a brain disease (Source: WebMD Health)
Source: WebMD Health - January 27, 2016 Category: Consumer Health News Source Type: news

MS Drug Tied to Higher Risk for Potentially Deadly Brain Virus
Patients taking Tysabri were more prone to show signs of exposure to JCV, which can cause a brain disease Source: HealthDay Related MedlinePlus Page: Multiple Sclerosis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - January 27, 2016 Category: Consumer Health News Source Type: news

More Tysabri Patients Turn Positive for JC Virus Antibodies (CME/CE)
(MedPage Today) -- Seroconversion rates on treatment much higher than expected (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - January 27, 2016 Category: Neurology Source Type: news

PML With Natalizumab Despite Recent Negative JCV Test ResultPML With Natalizumab Despite Recent Negative JCV Test Result
Because the first sign of PML was seen in new MRI findings, this case report underlines the value of surveillance imaging in patients receiving natalizumab, researchers say. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 14, 2016 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Natalizumab in the Pediatric MS PopulationNatalizumab in the Pediatric MS Population
Is natalizumab safe and effective for use in pediatric MS patients who have not responded to other therapies? BMC Neurology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 11, 2015 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news